NCT06154668 Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
| NCT ID | NCT06154668 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 707 participants |
| Start Date | 2024-01-17 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 707 participants in total. It began in 2024-01-17 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse events, evaluate the clinical benefit of adjuvant treatment /risk of relapse and design new strategies for non-responder patients. Thus, this project aims at understanding the impact of anti-PD1 on the immune system through investigation of the phenotypic, functional, metabolic and transcriptomic profiles of circulating DC subsets and effectors in response to anti-PD1 therapy in melanoma patients. The primary objective of the study is to identify the biomarkers of response to anti-PD1 according to the type of patient before the start of the treatment.
Eligibility Criteria
Inclusion Criteria: * Patient with histologically confirmed melanoma (stage I, II, III or IV based on AJCC classification) * Able to sign the informed collection consent for the retrospective part or to express their non-opposition to the research for the prospective part of the study Exclusion Criteria: * Subject under guardianship or subject deprived of freedom * Persons benefiting from special protection (as defined in Articles L1121-5 and L1121-8 of the Public Health Code): minors, pregnant or breastfeeding women, adults protected by law (under guardianship, curatorship or deprived of liberty) and persons hospitalized without their consent (as defined in Articles L3212-1 and L3212-3 of the Public Health Code). * ocular melanoma
Contact & Investigator
Julie Charles, MD, PhD
PRINCIPAL INVESTIGATOR
CHU Grenoble Alpes
Frequently Asked Questions
Who can join the NCT06154668 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06154668 currently recruiting?
Yes, NCT06154668 is actively recruiting participants. Contact the research team at jcharles@chu-grenoble.fr for enrollment information.
Where is the NCT06154668 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT06154668 clinical trial?
NCT06154668 is sponsored by University Hospital, Grenoble. The principal investigator is Julie Charles, MD, PhD at CHU Grenoble Alpes. The trial plans to enroll 707 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.